90Y-DOTA-nimotuzumab: Synthesis of a Promising β⁻ radiopharmaceutical

Teresa Scotognella, Daria Maccora, Isabella Bruno, Marco Chinol, Massimo Castagnola, Francesco Collamati, Carlo Mancini-Terraciano, Silvio Morganti, Valerio Bocci, Elena Solfaroli Camillocci, Dante Rotili, Antonella Cartoni, Ilaria Fratoddi, Federica Marini, Iole Venditti, Riccardo Faccini, Alessandro Giordano

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, nowadays used for tumour immunochemotherapy. This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a β- emitting radioimmunoconjugate (90Y-DOTA-nimotuzumab) potentially useful to assess the feasibility of a new radio-guided surgery approach.

METHODS: The synthesis of 90Y-DOTA-nimotuzumab was performed in two days. Nimotuzumab was conjugated with a 50 fold excess of DOTA and then labelled with 90Y3+. The 90Y-DOTA-nimotuzumab preparation was optimized considering several parameters such as pH, temperature and reaction volume. Moreover, the 90Y-DOTA-nimotuzumab stability was evaluated in human plasma.

RESULTS: The radioimmunoconjugate 90Y-DOTA-nimotuzumab was obtained with a radiochemical purity greater than 96%, and showed a good stability at 20°C as well as at 37°C in human plasma.

CONCLUSIONS: The optimized conditions for a mild and easy preparation of 90Y-DOTA-nimotuzumab joined to a promising stability under physiological conditions suggest to propose this radioimmunoconjugate as a potential diagnostic radiopharmaceutical for β- radio-guided surgery.

Original languageEnglish
JournalCurrent Radiopharmaceuticals
Publication statusE-pub ahead of print - Jan 4 2021


Dive into the research topics of '90Y-DOTA-nimotuzumab: Synthesis of a Promising β⁻ radiopharmaceutical'. Together they form a unique fingerprint.

Cite this